Sparks commentary - Herantis Pharma

Healthcare

Sparks - Herantis Pharma

More on this equity
Herantis (HEL: HRTIS) presents positive Phase Ib update
Published by Arron Aatkar, PhD

Herantis Pharma has announced an encouraging update from its ongoing Phase Ib trial for lead asset HER-096, which is being developed as a potential disease-modifying treatment for Parkinson’s disease (PD). Analysis of the part 1 of the Phase 1b trial provided new pharmacokinetic data for HER-096, confirming the expected dosing interval of 2 or 3 subcutaneous doses per week. Further, part 2 of the study has commenced, including the first dosing of a participant diagnosed with PD. Top-line data are anticipated in Q325.

 

 

Latest

Industrials | Comment

Earnz (AIM: EARN) – Proposed acquisition of Zero Carbon Group

Industrials | Comment

Electro Optic Systems (ASX: EOS) announces US$45m order win

Financials | Comment

Revolut secures full UK banking licence

Healthcare | Comment

OSE Immunotherapeutics (PAR: OSE) confirms new CEO